

- 57 Portela-Gomes GM, Stridsberg M, Grimeilius L, Rorstad O, Janson ET: Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas – predominance of receptor subtype 4. *Endocr Pathol* 2007;18:79–85.
- 58 Hofland LJ, Lamberts SW: The pathophysiological consequences of somatostatin receptor internalization and resistance. *Endocr Rev* 2003;24:28–47.
- 59 Jacobs S, Schulz S: Intracellular trafficking of somatostatin receptors. *Mol Cell Endocrinol* 2008;286:58–62.
- 60 Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S: Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. *J Clin Endocrinol Metab* 2009;94:654–661.
- 61 Reubi JC, Waser B, Cascato R, Gloor B, Stettler C, Christ E: Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. *J Clin Endocrinol Metab* 2010;95:2343–2350.
- 62 Fjällskog ML, Ludvigsen E, Stridsberg M, Öberg K, Eriksson B, Janson ET: Expression of somatostatin receptor subtypes 1–5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. *Med Oncol* 2003;20:59–67.
- 63 Reubi JC: Peptide receptor expression in GEP-NET. *Virchows Arch* 2007;451(suppl 1):S47–S50.
- 64 Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JG: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. *Cancer Res* 1989;49:7002–7009.
- 65 Reubi JC, Kvols L, Krenning E, Lamberts SW: Distribution of somatostatin receptors in normal and tumor tissue. *Metabolism* 1990;39:78–81.
- 66 Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW: Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. *Cancer Res* 1987;47:5758–5764.
- 67 Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SW: Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. *Am J Pathol* 1989;134:337–344.
- 68 De Sá SV, Corrêa-Giannella ML, Machado MC, de Souza JJ, Pereira MA, Patzina RA, Siqueira SA, Machado MC, Giannella-Neto D: Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. *Endocr Relat Cancer* 2006;13:69–78.
- 69 Cordelier P, Estève J-P, Bousquet C, Delesque N, O'Carroll A-M, Schally AV, Vaysse N, Susini C, Buscail L: Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. *Proc Natl Acad Sci USA* 1997;94:9343–9348.
- 70 Sharma K, Patel YC, Srikant CB: C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. *Mol Endocrinol* 1999;13:82–90.
- 71 Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A, Delle Fave G: Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. *Neuroendocrinology* 2009;89:223–230.

Erratum

In the paper by Costantini et al. [*Neuroendocrinology* 2011;94:158–168], an additional co-author (Angelo Bifone) has been added. The authors are now given as follows:

Vivian J.A. Costantini Elena Vicentini Fabio M. Sabbatini Enzo Valerio
Stefano Lepore Michela Tessari Matteo Sartori Francesca Michielin
Sergio Melotto Angelo Bifone Emilio Merlo Pich Mauro Corsi